Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05851365 · ClinicalTrials.gov registry record · Early Phase 1
Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer
A Early Phase 1 study of Prostate Cancer and Localized Prostate Carcinoma, sponsored by Robert Flavell, MD, PhD.
- Active
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT05851365 is a Early Phase 1 study of Prostate Cancer and Localized Prostate Carcinoma that is active but no longer recruiting, run by Robert Flavell, MD, PhD. The registered enrollment target is 1 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05851365, a Early Phase 1 study of Prostate Cancer and Localized Prostate Carcinoma, is active but no longer recruiting, sponsored by Robert Flavell, MD, PhD.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single site, prospective pilot study to determine the feasibility and safety of the administration of HP 13C bicarbonate in 10 patients with prostate cancer to determine potential hydrogen (pH) values in surrounding tissue. The proposed study will evaluate pre-surgical participants with histologically confirmed localized prostate cancer who receive infusion of hyperpolarized 13C injection prior to MR imaging with endorectal coil.
Conditions Studied
Interventions
- DRUG Hyperpolarized Bicarbonate (13C)
- PROCEDURE Magnetic Resonance imaging
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-07-06 |
| Est. Completion | 2025-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05851365
The ClinicalTrials.gov registry entry for NCT05851365 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Robert Flavell, MD, PhD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Hyperpolarized Bicarbonate (13C) is the first listed.
NCT05851365 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05851365 about?
NCT05851365 is a clinical study titled "Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer". This is a single site, prospective pilot study to determine the feasibility and safety of the administration of HP 13C bicarbonate in 10 patients with prostate cancer to determine potential hydrogen (pH) values in surrounding tissue. The proposed study will evaluate pre-surgical participants with hi...
What is the current status of trial NCT05851365?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2023-07-06. Estimated completion is 2025-12-31.
What conditions does trial NCT05851365 study?
This clinical trial studies the following conditions: Prostate Cancer, Localized Prostate Carcinoma.
What interventions are being tested in trial NCT05851365?
The interventions under investigation include: Hyperpolarized Bicarbonate (13C) (DRUG), Magnetic Resonance imaging (PROCEDURE).
Who is sponsoring clinical trial NCT05851365?
This trial is sponsored by Robert Flavell, MD, PhD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05851365 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
RECRUITING · Early Phase 1
-
Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer
RECRUITING · Early Phase 1
-
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
RECRUITING · Early Phase 1
-
Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
RECRUITING · Early Phase 1
-
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
RECRUITING · Early Phase 1
-
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer
ACTIVE NOT RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.